Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients

Luo,He‑Ting; Zhang,Jin‑Pei; Miao,Feng

doi:10.3892/etm.2016.3471

Effects of pramipexole treatment on the α-synuclein content in serum exosomes of Parkinson's disease patients

Authors:
- He‑Ting Luo
- Jin‑Pei Zhang
- Feng Miao
View Affiliations

Affiliations: Department of Geriatrics, Xianyang Central Hospital, Xianyang, Shaanxi 712000, P.R. China, Department of Encephalopathy, Affiliated Hospital of the Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi 712000, P.R. China
Published online on: June 21, 2016 https://doi.org/10.3892/etm.2016.3471
Pages: 1373-1376
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Advances approaches in the treatment of Parkinson's disease are needed. The study was aimed to evaluate the therapeutic value of the new dopamine receptor agonist pramipexole. The effects of pramipexole on serum exosomes were investigated, and the possible mechanisms of action of the drug were explored. Initially, 68 patients were included in the study, of whom 3 cases did not complete the study. The remaining 65 patients were administered pramipexole at increasing doses starting at 0.25 mg twice a day for the 1st week, and reaching 1.5 mg three times daily at the 8th week. The doses were tapered during the course of the following 4 weeks. The total scores of the motor examination of the unified Parkinson's disease rating scale III (UPDRS III) and the total scores of the daily life activity in UPDRS II were compared before and after treatment. The relative expression amounts of α‑synuclein in serum exosomes were then calculated by western blot analysis. Scores of UPDRS III and UPDRS II following treatment were significantly lower than the scores prior to treatment, and the difference was statistically significant (P<0.05). The relative expression of α‑synuclein in serum exosomes was also found to be significantly lower after treatment (P<0.05). The relative expression of α‑synuclein in the effective treatment group was significantly lower than that in the ineffective treatment group, and the difference was statistically significant (P<0.05). The relative expression of α‑synuclein in serum exosomes was significantly correlated with treatment effects (P<0.05). In conclusion, pramipexole was effective and safe as a treatment for Parkinson's disease. The therapeutic effect of pramipexole may be associated with its reducing effect on the relative expression of α‑synuclein in serum exosomes.

View Figures

View References

1	Lees AJ, Hardy J and Revesz T: Parkinson's disease. Lancet. 373:2055–2066. 2009. View Article : Google Scholar : PubMed/NCBI
2	Shulman JM, De Jager PL and Feany MB: Parkinson's disease: Genetics and pathogenesis. Annu Rev Pathol. 6:193–222. 2011. View Article : Google Scholar : PubMed/NCBI
3	Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L and Vekrellis K: Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 30:6838–6851. 2010. View Article : Google Scholar : PubMed/NCBI
4	Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ and Cooper JM: Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 42:360–367. 2011. View Article : Google Scholar : PubMed/NCBI
5	van Niel G, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N and Heyman M: Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology. 121:337–349. 2001. View Article : Google Scholar : PubMed/NCBI
6	Théry C, Amigorena S, Raposo G and Clayton A: Isolation and characterization of exosomes from cell culture supematants and biological fluids. Curr Protoc Cell Biol Chapter. 3:Unit 3.22. 2006. View Article : Google Scholar
7	Johnstone RM, Adam M, Hammond JR, Orr L and Turbide C: Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 262:9412–9420. 1987.PubMed/NCBI
8	Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G and Bonnerot C: Exosomal-like vesicles are present in human blood plasma. Int Immunol. 17:879–887. 2005. View Article : Google Scholar : PubMed/NCBI
9	Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J and Amigorena S: Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol. 166:7309–7318. 2001. View Article : Google Scholar : PubMed/NCBI
10	Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, et al: Exosomes are released by cultured cortical neurones. Mol Cell Neurosci. 31:642–648. 2006. View Article : Google Scholar : PubMed/NCBI
11	Potolicchio I, Carven GJ, Xu X, Stipp C, Riese RJ, Stern LJ and Santambrogio L: Proteomic analysis of microglia-derived exosomes: Metabolic role of the aminopeptidase CD13 in neuropeptide catabolism. J Immunol. 175:2237–2243. 2005. View Article : Google Scholar : PubMed/NCBI
12	Théry C, Ostrowski M and Segura E: Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 9:581–593. 2009. View Article : Google Scholar : PubMed/NCBI
13	Chivet M, Hemming F, Pernet-Gallay K, Fraboulet S and Sadoul R: Emerging role of neuronal exosomes in the central nervous system. Front Physiol. 3:1452012. View Article : Google Scholar : PubMed/NCBI
14	Lachenal G, Pernet-Gallay K, Chivet M, Hemming FJ, Belly A, Bodon G, Blot B, Haase G, Goldberg Y and Sadoul R: Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci. 46:409–418. 2011. View Article : Google Scholar : PubMed/NCBI
15	Panaro MA and Cianciulli A: Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson's disease. Curr Pharm Des. 18:200–208. 2012. View Article : Google Scholar : PubMed/NCBI
16	Stoorvogel W, Kleijmeer MJ, Geuze HJ and Raposo G: The biogenesis and functions of exosomes. Traffic. 3:321–330. 2002. View Article : Google Scholar : PubMed/NCBI
17	El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG and Allsop D: Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20:419–425. 2006. View Article : Google Scholar : PubMed/NCBI
18	Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, Nakagawa M and El-Agnaf OM: Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 75:1766–1772. 2010. View Article : Google Scholar : PubMed/NCBI
19	Hansen C, Angot E, Bergström AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, et al: α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 121:715–725. 2011. View Article : Google Scholar : PubMed/NCBI
20	Danzer KM, Kranich LR, Ruf WP, Cagsal-Getkin O, Winslow AR, Zhu L, Vanderburg CR and McLean PJ: Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 7:422012. View Article : Google Scholar : PubMed/NCBI
21	Ghidoni R, Benussi L and Binetti G: Exosomes: The Trojan horses of neurodegeneration. Med Hypotheses. 70:1226–1227. 2008. View Article : Google Scholar : PubMed/NCBI
22	Mierau J and Schingnitz G: Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol. 215:161–170. 1992. View Article : Google Scholar : PubMed/NCBI